ProCE Banner Activity

PemCab: Phase II Study of First-line Cabozantinib + Pembrolizumab for Cisplatin- or Platinum-Ineligible Patients With aUC

Conference Coverage

Promising efficacy with a reasonable safety profile was seen with the combination of cabozantinib and pembrolizumab as first-line therapy in patients with cisplatin- or platinum-ineligible locally advanced or metastatic urothelial cancer in the phase II PemCab trial.

Released: February 02, 2024


Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by educational grants from AstraZeneca, Exelixis, Inc., and Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.


Exelixis, Inc.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC